Is Tesamorelin from Lumera Labs HPLC verified?

Yes. Every Tesamorelin lot Lumera Labs ships is HPLC-purity tested at synthesis and retested by Janoshik Analytical before release. The lot-specific Certificate of Analysis is published on the Lab Results page.

Is Tesamorelin sold for human use?

No. Tesamorelin is sold strictly as a laboratory reference standard for in-vitro research. It is not approved by Health Canada or the FDA for human use. Every order requires a research-use declaration.

How is Tesamorelin shipped?

Tesamorelin is lyophilized at synthesis, sealed under nitrogen, and shipped from Kelowna, BC at -20 C through cold-chain insulated packaging via Canada Post Xpresspost. Free shipping over $200 CAD. 24-48h transit Canada-wide.

Where can I see the COA for Tesamorelin?

Each shipment includes a lot-specific Certificate of Analysis. The current lot's COA is also published at https://lumerapeptide.com/lab-results/ and can be cross-referenced by the batch number printed on each vial.

Home / Catalog / Growth Axis / Tesamorelin 10 mg

4.7 · 238 researcher reviews

Growth axis · GHRH analog

Tesamorelin

SKU LUM-TESA-2 · C₂₂₁H₃₆₆N₇₂O₆₇S · 5135.86 g/mol · CAS 901758-09-6

A synthetic 44-residue analog of human growth-hormone-releasing hormone with N-terminal trans-3-hexenoyl modification for protease resistance.

Purity (HPLC): ≥ 99.25%
Net peptide: 5.00 mg ± 2%
Endotoxin: < 0.5 EU/mg
Format: Lyophilized vial
Storage: −20 °C, desiccated
Shelf life: 24 months from MFG

$50CAD / 10 mg vial

In stock · Lot 26-A031

Bulk 10+: $24 / vial

Add $200 for free cold-chain shipping

HPLC + MS verified per lot
Cold-chain to your door
COA bundled with shipment
Lot retains kept 5 years

Overview

Tesamorelin is a synthetic analog of human GHRH(1-44) with a trans-3-hexenoyl group attached to the N-terminal tyrosine. The lipid modification confers resistance to dipeptidyl peptidase-IV cleavage, extending its functional half-life relative to native GHRH.

Each vial is lyophilized from acetate buffer, sealed under nitrogen, and shipped cold-chain at −20 °C from our Kelowna facility.

Research applications

GHRH-receptor activation potency assays, comparative DPP-IV resistance screens, pituitary GH-secretion studies, and visceral-adipose-tissue lipolysis models.

Sold for laboratory research only. This material is not a drug, food, or cosmetic and is not intended for diagnostic, therapeutic, or recreational use.

Identity

Parameter	Value
Sequence	trans-3-hexenoyl-Tyr¹-hGHRH(1-44)
Molecular formula	C₂₂₁H₃₆₆N₇₂O₆₇S
Molecular weight	5135.86 g/mol
CAS number	901758-09-6
Length	44 residues

Quality

Test	Specification
HPLC purity	≥ 99.0% (lot LM-2642: 99.06%)
Mass confirmation	ESI-MS within 0.5 Da
Net peptide content	≥ 80% by AAA
Endotoxin	< 0.5 EU/mg (LAL)
Bioburden	< 10 CFU/g
Residual TFA	< 1.0%

Lot LM-2642

Manufactured 04 Mar 2026 · Released 11 Mar 2026 · Tested by Lumera QC, Kelowna BC. Retain samples held under storage spec for five years from release date.

Verification

Method	Result
RP-HPLC at 220 nm	99.06% main peak
ESI-MS (positive)	5135.9 Da (theor. 5135.86)
Amino acid analysis	82.1% net peptide
LAL endotoxin	< 0.05 EU/mg
Karl Fischer (water)	2.8% w/w

Reconstitution

Allow vial to reach room temperature before opening (≥ 20 minutes). Reconstitute with 1.0–2.5 mL of sterile bacteriostatic water (0.9% benzyl alcohol). Inject solvent slowly down the inner wall of the vial; do not direct stream onto the lyophilized cake.

Swirl gently for 30 seconds. Do not vortex. Allow to dissolve for 5 minutes; clarity should be complete with no visible particulates.

Storage after reconstitution

Reconstituted solution is stable for 28 days at 2–8 °C in original vial. For longer storage, aliquot into low-binding tubes and hold at −80 °C; avoid repeated freeze-thaw cycles. Discard if turbidity, color change, or particulate matter is observed.